logo-loader
RNS
MaxCyte

Annual Report

/**/ h1{margin-right:0cm;margin-left:0cm;text-align:left;line-height:normal;font-size:24.0pt;font-family:"Times New Roman","serif";font-weight:bold;}p{margin-top:3.75pt;margin-right:0cm;margin-bottom:7.5pt;margin-left:0cm;text-align:justify;line-height:13.5pt;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .cg{size:595.3pt 841.9pt;margin:63.8pt 72.0pt 56.75pt 72.0pt;}div.cg{}p.ds{margin:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;font-size:12.0pt;font-family:"Arial","sans-serif";font-weight: bold; text-align: center}span.dq{font-size:14.0pt;font-family:"Calibri","sans-serif"}p.dt{margin:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;font-size:12.0pt;font-family:"Arial","sans-serif";text-align: center}span.do{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.du{margin:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;font-size:12.0pt;font-family:"Arial","sans-serif";line-height:112%}span.dm{font-size:11.0pt; line-height:112%;font-family:"Calibri","sans-serif"}span.dk{font-size:11.0pt;line-height:112%;font-family: "Calibri","sans-serif"}span.dj{font-size:11.0pt;line-height:112%;font-family:"Calibri","sans-serif"; color:black} span.ce{}span.di{font-size:11.0pt;line-height:112%; font-family:"Calibri","sans-serif"}span.dv{font-size:11.0pt;line-height:112%;font-family:"Calibri","sans-serif"; color:black}span.dh{font-size:11.0pt; line-height:112%;font-family:"Calibri","sans-serif";color:black}p.dw{margin:0cm;margin-bottom:.0001pt;text-align:left;line-height:normal;text-autospace:none;font-size:12.0pt;font-family:"Bradley Hand ITC";color:black;font-weight: bold; line-height: 150%; text-align: justify; text-autospace: ideograph-numeric ideograph-other}span.dg{font-size:11.0pt;line-height: 150%;font-family:"Calibri","sans-serif"}p.dx{margin:0cm;margin-bottom:.0001pt;text-align:left;line-height:normal;text-autospace:none;font-size:12.0pt;font-family:"Bradley Hand ITC";color:black;font-weight: bold; line-height: 112%; text-align: justify; text-autospace: ideograph-numeric ideograph-other}span.de{font-size:11.0pt;line-height: 112%;font-family:"Calibri","sans-serif"}p.dy{margin:0cm;margin-bottom:.0001pt;text-align:left;line-height:normal;text-autospace:none;font-size:12.0pt;font-family:"Bradley Hand ITC";color:black;text-align:justify;line-height:112%;text-autospace: ideograph-numeric ideograph-other}span.dc{font-size:11.0pt;line-height:112%;font-family:"Calibri","sans-serif"} p.dz{margin:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;font-size:12.0pt;font-family:"Arial","sans-serif";line-height:150%}span.da{font-size:11.0pt; line-height:150%;font-family:"Calibri","sans-serif"}p.ea{margin:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;font-size:12.0pt;font-family:"Arial","sans-serif";margin-left:-4.5pt;line-height:150%}span.cy{font-size:11.0pt;line-height:150%;font-family:"Calibri","sans-serif"}table.eb{width:472.5pt;margin-left:-10.8pt;border-collapse:collapse}tr.cs{height:14.05pt}td.cu{width:256.9pt;padding:0cm 5.4pt 0cm 5.4pt; height:14.05pt}p.ec{margin:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;font-size:12.0pt;font-family:"Arial","sans-serif";font-weight: bold; line-height: 150%}span.cv{font-family:"Calibri","sans-serif"}td.ct{width:194.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:14.05pt} tr.cn{height:92.7pt}td.cp{width:256.9pt;padding:0cm 5.4pt 0cm 5.4pt; height:92.7pt}p.ed{margin:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;font-size:12.0pt;font-family:"Arial","sans-serif";font-div: italic; font-weight: bold; line-height: 150%}span.cr{font-size: 11.0pt;line-height:150%;font-family:"Calibri","sans-serif"}td.co{width:194.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:92.7pt}tr.ci{height:101.25pt}td.ck{width:256.9pt;padding:0cm 5.4pt 0cm 5.4pt; height:101.25pt}span.cm{font-size:11.0pt; line-height:150%;font-family:"Calibri","sans-serif";color:black}span.cl{font-family: "Calibri","sans-serif"}td.cj{width:194.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:101.25pt} p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;font-size:12.0pt;font-family:"Arial","sans-serif";} /**/
RNS Number : 7254C
MaxCyte, Inc.
19 June 2019
 

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

2018 Annual Report

 

 

Gaithersburg, Maryland - 19 June 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company,  announces that copies of the 2018 Annual Report and Accounts have been sent to Stockholders and are available on the "Investors" section of the Company's website at www.maxcyte.com.

 

MaxCyte also announces that its Annual General Meeting of Stockholders is planned to be held on 31 October 2019. Formal notice and resolutions, along with the Annual Meeting Proxy Card, will be circulated in September 2019 to Stockholders of record at that time.

 

About MaxCyte

MaxCyte is a clinical-stage global cell-based medicines and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA™ therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies. The Company now has more than 70 partnered program licenses in cell therapy with more than 35 licensed for clinical use, including four announced commercial licenses covering potentially more than 30 products with aggregate potential milestones of more than $250M. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.

 

For further information, please contact:

 

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

 

+1 301 944 1660

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl

Freddy Crossley

Corporate Broking

James Stearns

 

 

+44 (0)20 7886 2500

Joint Corporate Broker

Numis Securities Limited

James Black

Duncan Monteith

 


+44 (0)20 7260 1000

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Sukaina Virji

 

+44 (0)203 709 5700

[email protected]

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ACSGUGDLXUBBGCC

Quick facts: MaxCyte

Price: £1.24

Market: AIM
Market Cap: £71.04 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18